Intra Uterine Fetal Death Clinical Trial
— MISOfficial title:
Intra Uterine Extra Amniotic (200 μg ) Versus Vaginal (200 μg) Misoprostol for Second Trimester Pregnancy Termination: Randomized Controlled Trial
Verified date | January 2016 |
Source | Assiut University |
Contact | n/a |
Is FDA regulated | No |
Health authority | Egypt: Institutional Review Board |
Study type | Interventional |
The majority of second-trimester pregnancy termination performed in the United States are performed surgically by dilation and evacuation. The frequency of induction of abortion increases as gestational age advances. In the late second trimester and early third trimester, induction is the primary method of termination in cases of fetal abnormalities. In many other countries, however, induction is the primary method of abortion throughout the second trimester
Status | Completed |
Enrollment | 180 |
Est. completion date | January 2016 |
Est. primary completion date | December 2015 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | N/A and older |
Eligibility |
Inclusion Criteria: - Pregnancy 13-24 weeks. - Women with indication for termination of the pregnancy due to intra uterine fetal death Exclusion Criteria:-Pregnancy before 13 weeks. - Pregnancy beyond 24 weeks. - Women with scared uterus. - Known hypersensitivity for misoprostol. - Refusal of the woman to participate. |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Assiut University |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | mean duration from the initial misoprostol dose until complete fetal expulsion | 24 hours | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03067298 -
Prediction of Preeclampsia and Other Pregnancy Complications Following Combined Iterative Screening
|